Maximus at 8x Earnings: Cheap Stock or Government Cheese Nobody Wants?

# Maximus at 8x Earnings: Cheap Stock or Government Cheese Nobody Wants?

Here's a fun exercise: find a company growing EBITDA margins, beating EPS estimates, raising guidance, and buying back its own stock hand over fist — then check why it's trading at 8 times trailing earnings and down over 30% year-to-date. Welcome to Maximus, the largest pure-play operator of the unglamorous plumbing of American government — Medicaid eligibility checks, Medicare appeals, VA disability exams, unemployment insurance processing. Nobody puts this stuff on a vision board, but somebody has to run it, and for years that somebody has been Maximus, at a very healthy margin.

Last Thursday, August 6, the company reported its Q3 FY2026 numbers, and it was the market's favorite kind of confusing print: revenue of $1.28 billion, down 5.1% year-over-year and short of the Street's $1.33 billion — but adjusted EPS of $2.22 squeaked past the $2.21 consensus. A miss on the top, a beat on the bottom, in a stock that's already been taken to the woodshed all year. That's the kind of headline that sends quant screens into a tizzy and human investors into a shrug.

Zoom out to Q2, reported back in May, and the pattern holds: revenue slipped to $1.31 billion from $1.36 billion a year earlier, yet Maximus raised full-year earnings guidance, authorized a fresh buyback, and pushed adjusted EBITDA margin up to 14.4%, with management crediting "efficiency gains and AI." Translation: the top line is shrinking, but they're squeezing more profit out of what's left. That's either disciplined management or a company running out of runway and monetizing the exit — depends who you ask.

The bull case, in one sentence: DOGE can gut discretionary federal programs all it wants, but Medicaid eligibility, Medicare appeals, and VA claims processing are mandatory spending, and mandatory spending doesn't get zeroed out by a budget memo. Federal segment revenue reportedly keeps growing 7-10% as VA claims stay elevated and CMS piles on more program administration work. Layer on a 21% ROE, a 2.21 current ratio, a dividend that's barely denting free cash flow (18% payout ratio), and a stock priced at roughly 8x trailing earnings against consensus expectations of ~10% EPS growth next year, and you've got a textbook "market is wrong" setup.

The bear case is simpler and less cute: revenue is falling, and it's falling in back-to-back quarters. DOGE-related contract cancellations in federal IT have already happened — this isn't hypothetical risk, it's a line item. The comforting distinction between "mandatory" and "discretionary" government spending sounds great in an investor deck, but political risk doesn't respect taxonomies when budget season gets ugly. And with only two analysts covering the stock and price targets scattered from $85 to $125, there's not exactly a deep bench of smart money forcing efficient pricing here. Thin coverage plus a falling knife is how "cheap" quietly becomes "trap."

Here's my read: the debt load — debt/equity flirting with 1.0 — combined with two straight quarters of revenue contraction is the real tell, not the DOGE narrative. Margin expansion is real and welcome, but you can't cost-cut your way to growth forever, and the balance sheet doesn't have infinite patience if the top line keeps eroding. That said, at 8x earnings with a 21% ROE and management actively buying back stock while raising guidance, this isn't a broken company — it's a boring, profitable one trading like the market expects a recession in federal Medicaid outlays that hasn't shown up in the numbers yet.

The technical picture backs up the "wait, don't chase" instinct — the stock's chopping around $59 with support at the 52-week low of $52.73 and resistance at $60 that hasn't been tested with any conviction. This is not a chart begging you to back up the truck today.

My take: Maximus is a legitimate value name wearing a "falling revenue" scarlet letter, and the next real verdict comes with Q4/full-year results in early-to-mid November, when we find out if the margin story can keep outrunning the top-line story. Until then, this is a stock for people who like getting paid a dividend to be patient — not a stock for anyone looking for a catalyst-driven pop. Buy the balance sheet and the buyback; just don't pretend the revenue trend isn't the whole ballgame.